Abstract

Tair Lapidot

Nasus Pharma developed Taffix®-An innovative nasal powder personal spray comprised of low-pH Hypromellose which forms a protective mechanical barrier that prevents viruses from engaging with nasal cells and deactivates viruses. Taffix® was found to be a significant protective tool for preventing airborne viral infections, including by SARS-CoV-2 in addition to the multiple preventive measures taken today. Taffix is safe and biocompatible. Nasus has tested its products in several in vitro efficacy studies with multiple virus strains, including a few variants of SARS-CoV-2 (Hong Kong/VM20001061/2020; Alpha; Beta and Delta Israel isolate; lentivirus and influenza). Taffix® spray blocked passage of all four tested SARS-CoV-2 variants, as demonstrated by a 99%-100% reduction of recoverable viral RNA from Vero-E6 cells or by plaque assay, Taffix® was tested in human real-life, high infection risk setting during the COVID-19 pandemic (September 2020): In a prospective two-week user survey completed by 243 individuals participating in a two-day mass-gathering event in a highly endemic community, none of the 81 individuals who regularly applied Taffix® nasal spray during the event and the subsequent two weeks reported on SARS-CoV-2 infection (verified by PCR). In contrast, of the 18 individuals who tested SARS-CoV-2-positive in the subsequent two weeks, 16 (98%) did not use Taffix® and the remaining two individuals report using it once or twice in the study period? No side effects were reported.

Taffix® is legally marketed in Europe, Israel and more and additional clinical data is being collected.